Calcified Iliac vessels
This is an observational study, which means it does not change the care that patients receive. Everyone taking part will already have received intravascular lithotripsy (IVL) as part of their normal treatment for blocked and calcified arteries. The study simply collects information about what happens AFTER this treatment has taken place. Before treatment (screening and consent): Patients will be identified from routine clinic visits, hospital wards or operating lists. If they are interested, they will be given written information about the study and time to consider it. If they agree to take part, they will sign a consent form. No tests or procedures are done just for the study. At the time of treatment (day 0): The IVL procedure is carried out exactly as planned by the clinical team, following normal hospital practice. The study team records information that is already routinely collected, such as details of the artery treated, the devices used, and whether the artery is successfully opened at the end of the procedure. After treatment (follow-up): Participants are followed up for up to 12 months. Information is collected at approximately: 1. 30 days 2. 3 months 3. 6 months 4. 12 months Most follow-up is done by reviewing medical records and by short telephone calls with the participant. These calls ask about recovery, any hospital admissions, further procedures, or new health problems. If participants attend hospital clinics or have scans as part of normal care, those results are also recorded. The only difference from standard care is the follow-up telephone calls by the research team. No extra hospital visits, scans or treatments are required for the study. No one will receive additional radiation or any other intervention (e.g., surgery or extra treatment) if they take part in the research. The study records how well the artery stays open, whether further treatment is needed, any complications or hospital admissions, and basic information about treatment c
1. Adults aged 18 years or older 2. A diagnosis of symptomatic peripheral arterial disease (PAD), meaning reduced blood flow to the legs causing symptoms such as pain when walking or more severe limb symptoms 3. PAD classified as Rutherford stages 3 to 5, indicating moderate-to-severe symptoms that require treatment 4. Presence of calcified narrowing or blockage of the arteries supplying the pelvis or lower part of the main body artery (femoral, iliac or aorto-iliac arteries), confirmed on routine clinical imaging 5. The patient has already been selected by their treating clinical team to undergo intravascular lithotripsy (IVL) as the primary treatment, as part of their normal NHS or hospital care, independent of the study 6. Treatment with IVL has taken place within routine clinical practice at a participating hospital site 7. The patient is willing and able to provide written informed consent to take part in the study, including consent for the use of their routine clinical data and follow-up information for research purposes These criteria ensure that the study includes patients who would normally receive IVL L6 for calcified femoral, iliac or aortoiliac artery disease without altering clinical decision-making or standard care pathways.
1. Under 18 years of age 2. Asymptomatic peripheral arterial disease, or PAD, not meeting Rutherford stage 3–5, where treatment with intravascular lithotripsy (IVL) is not clinically indicated 3. No significant arterial calcification in the femoral, iliac or aortoiliac arteries, or where IVL is not considered appropriate by the treating clinical team 4. Patients who do not receive IVL l6 as the primary treatment strategy for the target femoral, iliac or aorto-iliac lesion. 5. Patients in whom an alternative revascularisation strategy is used instead 6. Inability to provide informed consent, including lack of capacity to consent and no appropriate consultee process available. 7. Withdrawal of consent at any time prior to or during the study 8. Patients who are unwilling or unable to participate in follow-up, including refusal of follow-up contact or inability to be contacted by telephone These exclusion criteria ensure that the study population is limited to adults with symptomatic, calcified iliac or aorto-iliac peripheral arterial disease who are able to provide consent and are receiving IVL as part of routine clinical care.